^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

TEST:
Xpert® BCR-ABL Ultra

Company:
Danaher Corp
Type:
FDA Approved
Related tests:

Details

Evidence
The Xpert BCR-ABL Ultra test is an in vitro diagnostic test for the quantitation of BCRABL1 and ABL1 mRNA transcripts in peripheral blood specimens of diagnosed t(9;22) positive Chronic Myeloid Leukemia (CML) patients expressing BCR-ABLl fusion transcripts type e13a2 and/or e14a2. The test utilizes automated, quantitative, real-time reverse transcription polymerase chain reaction (RT-qPCR). The Xpert BCR-ABL Ultra test is intended to measure BCR-ABL1 to ABL1 percent ratios on the International Scale (IS), and also expressed as a log molecular reduction (MR value) from a baseline of 100% (IS), in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).
Cancer:
Chronic Myeloid Leukemia
Gene:
ABL1 (ABL proto-oncogene 1), BCR (BCR Activator Of RhoGEF And GTPase)
Method:
RT-PCR
Approvals
Date
Cancer
Gene
Drug
By
09/27/19
FDA